ESR1 and breast carcinoma: FOXA1 overexpression comprises a major proliferation and survival signal for luminal type A breast cancer, which has been attributed to the amplification of FOXA1 in around 6% of primary tumors and 10% of metastatic ER+ (estrogen receptor positive) tumors [75,76].